Company* (Country, Symbol) | Company# (Country, Symbol) |
Type/Product Area |
Terms/Details (Month) |
Acadia Pharmaceuticals* | Allergan (NYSE:AGN) |
License and research collaboration agreement to discover, develop and commercialize compounds for glaucoma, based on Acadia's receptor subtype-selective muscarinic lead compounds |
Acadia will grant Allergan worldwide rights to products based on Acadia's novel lead compounds for treatment of ocular disease; Acadia will provide its expertise in medicinal chemistry and high-throughput pharmacology to enable the final selection of up to two candidates for clinical development and commercialization by Allergan; Acadia may receive up to $19M for the first development candidate in the form of up-front fees, research support and traditional milestone payments; Acadia will also receive royalties on future product sales worldwide; Allergan has the right to to select a second development candidate, subject to similar milestone and royalty payments to Acadia (7/99) |
Ambion Inc.* |
Gen-Probe Inc.* |
License agreement; Gen-Probe will receive non-exclusive worldwide rights to use Ambion's armored RNA technology in products and processes for clinical diagnostic use |
Gen-Probe will have the rights to manufacture armored RNA controls and standards for use in human diagnostic kits; further details ND (7/99) |
ATIII LLC (a joint venture between Genzyme Transgenics Corp., GZTC; and Genzyme General, GENZ) | Genzyme Molecular Oncology (GZMO) |
Collaboration agreement in which the two companies will develop and commercialize the angiogenesis inhibitor protein aaATIII as a potential treatment for cancer | Genzyme and ATIII LLC will equally share in the development costs of the potential therapeutic, and will equally share any profits from a successful product resulting from the collaboration; ATIII LLC will have the rights to develop the therapeutic for potential non-oncologic indications (9/99) |
Array BioPharma Inc.* |
Neurocrine Biosciences Inc. (NBIX) | Research collaboration for the design and synthesis of a focused library around small molecules targeted at G protein-coupled receptors |
Array will combine its expertise in the generation of small-molecule libraries with Neurocrine computational methodology; both companies will contribute unique, proprietary chemical templates to the collaboration; financial details ND (10/99) |
Tularik Inc. | License agreement for small-molecule libraries for screening against high-throughput screening assays | Tularik will gain nonexclusive access to Array's small-molecule libraries; financial details ND (8/99) |
|
Arena Pharmaceuticals Inc.* |
Neurocrine Biosciences Inc. (NBIX) | Research collaboration; Neurocrine will apply Arena's constitutive activation technology to three of its orphan G protein-coupled receptors | ND (9/99) |
Aurora Biosciences Corp. (ABSC) | Exelixis Pharmaceuticals Inc.* | License agreement in which Exelixis receives certain rights to use Aurora's green fluorescent protein technology (GFP), primarily for target identification and validation |
Aurora receives an up-front payment and annual fees; Exelixis may choose in the future to use Aurora's services regarding GFP screening assays for high- and ultra-high-throughput screening (9/99) |
Genentech Inc. (NYSE:DNA) |
License agreement in which Genentech receives certain rights to use Aurora's green fluorescent protein technology (GFP) for various in vitro and in vivo applications | Aurora receives an up-front payment and annual fees, as well as milestone payments for products developed using Aurora's technology; Genentech is granted certain rights to manufacture therapeutic proteins using the GFP technology (9/99) |
|
Axiom Biotechnologies Inc.* |
Oxford Molecular Group (UK; LSE: OMG) |
Development agreement | The companies announced completion of their agreement to co-develop Axiom's Profiler '99 Cell BioInformatics solution for cell profiling and high-speed automation to create databases of cell profiles for comprehensive secondary assay applications; financial details ND (8/99) |
Axys Advanced Technologies (a subsidiary of Axys Pharmaceuticals Inc.; AXPH) |
Allergan (NYSE:AGN) |
Research and development (R&D) collaboration using Axys's combinatorial chemistry technologies | Axys and Allergan entered a three-year agreement under which Axys will provide Allergan with a diverse compound screening library consisting of small-molecule compounds created using Axys' combinatorial chemistry technologies; Axys will also provide Allergan with enabling technologies for reproducing and expanding the library chemistries; Axys will receive an up-front payment and additional payments upon product delivery and technology transfer (10/99) |
Elitra Pharmaceuticals* | Collaboration agreement in which Axys will supply diverse compound screening libraries and chemistry services for use by Elitra in proprietary target-based assays in bacteria and fungi |
Axys will be paid by Elitra for the delivery of compounds, and will receive future payments if Elitra uses Axys for chemistry support and services (10/99) |
|
Biosite Diagnostics Inc. (BSTE) |
Corixa Corp. (CRXA) | Antibody development and licensing collaboration agreement |
Biosite will use its Discovery Omniclonal technology to generate antibodies for Corixa's use in conducting protein target research; Biosite will receive diagnostic rights to the markers under study, development fees and, if Corixa successfully commercializes an antibody product, milestones and royalties; if Biosite successfully commercializes a diagnostic product for such markers, Corixa could receive milestones and royalties (9/99) |
Cambridge Antibody Technology (UK; LSE:CAT) |
Human Genome Sciences (HGSI) |
R&D agreement for the development of fully human monoclonal antibody therapeutics; Cambridge will use its high-throughput antibody isolation technologies to generate high-affinity, fully human monoclonal antibodies specific for up to three target human proteins identified by and proprietary to Human Genome Sciences |
Cambridge could receive milestone and royalty payments on products and will receive research support funding (8/99) |
Cantab Pharmaceuticals plc (UK;CNTBY) | Celltech Therapeutics* (UK) | License agreement for the development of therapeutic antibodies to the OX40 receptor for chronic inflammatory and autoimmune disorders | Cantab granted Celltech an exclusive license to its OX40 antibody program; Cantab has a two-year option to buy into the development of products arising from the agreement; financial details ND (10/99) |
Celera Genomics (NYSE:CRA) | Gemini Research Ltd. (a subsidiary of Gemini Holdings plc*) |
R&D collaboration to discover genes and genetic polymorphisms associated with common, chronic, age-related diseases; the collaboration will combine Gemini's clinical genetics approach with Celera's DNA sequence information and computational gene discovery capability |
Celera and Gemini will commercialize the jointly owned results by jointly licensing the rights to discoveries to third parties; both parties will share in the revenues received from licensing fees, milestone payments and royalties arising from the collaboration (9/99) |
Cell Genesys Inc. (CEGE) | EntreMed Inc. (ENMD) |
Research collaboration to evaluate gene therapy for cancer; EntreMed's Angiostatin and Endostatin proteins will be combined with Cell Genesys' adenoviral and adeno-associated viral gene delivery systems | The two companies will consider a potential business relationship based on the results of the studies performed under this collaboration; financial details ND (8/99) |
Rigel Pharmaceuticals Inc.* |
Research collaboration and license agreement |
Rigel will employ its proprietary functional genomics technology to identify novel therapeutic genes for the treatment of cancer, and Cell Genesys will be granted exclusive, worldwide rights to these genes in the field of gene therapy; Rigel will gain access to certain Cell Genesys patents and technology pertaining to retroviral gene delivery technology; financial details ND (9/99) | |
Cellular Genomics Inc.* |
Oxford GlycoSciences (UK; LSE:OGS) | R&D collaboration focused on applying proteome analysis to the discovery of novel proteins and their associated genes involved in key processes in immune system modulation |
Cellular Genomics and Oxford will jointly pursue a program that includes exclusive access to Cellular's dendritic cell and T-cell populations; proteome mapping and analysis will be carried out by Oxford; financial details ND (9/99) |
Centeon LLC* |
Principia Pharmaceutical Corp.* | License agreement for Centeon's recombinant albumin fusion proteins and related yeast production technology for the treatment of cancer, viral diseases and growth deficiencies | Centeon will grant Principia exclusive, worldwide rights to recombinant albumin fusion proteins and related yeast production technology; Centeon will receive milestone payments, royalties, license fees and an equity position in Principia; Centeon will retain rights to fusion proteins within its core plasma protein business and in other areas (8/99) |
ChiRhoClin Inc.* (RGEN) | Repligen Corp. |
License agreement for in vivo diagnostic products based on the hormone secretin | Repligen will receive exclusive rights to two in vivo products based on the hormone secretin; Repligen will be responsible for product marketing and distribution following approval by the FDA, and will pay ChiRhoClin an up-front payment, development milestones and a royalty based on sales; ChiRhoClin will be responsible for regulatory affairs and manufacturing (10/99) |
Chiron Corp. (CHIR) |
Biomira Inc. (Canada; BIOM; TSE:BRA) | Revision of collaboration agreement; Biomira will reacquire all rights held by by Chiron to Theratope vaccine in order to involve a third party in the development and commercialization of the vaccine | Chiron will receive an undisclosed amount from Biomira to retain an ongoing interest in the development and commercialization of Theratope; the agreement is structured as a series of put and call options between the two companies, and may be modified over time (9/99) |
Corixa Corp. (CRXA) |
Introgen Therapeutics Inc.* |
License agreement; Corixa granted Introgen an exclusive worldwide license to the patented universal tumor suppressor gene, mda7, for use in gene therapy | Corixa will receive an up-front license fee, as well as undisclosed milestone payments, research and development payments and royalties on potential product sales (8/99) |
Corvas International Inc. (CVAS) |
Vascular Genomics Inc.* | Termination of option agreement |
Corvas will not exercise its option, acquired in 1997, to purchase Vascular Genomics; upon expiration or cancelation of the option, Vascular stockholders have a right to put 19.9% of Vascular stock to Corvas for a purchase price of $3.9M ($3 per share); instead, Corvas will issue the stockholders a total of 0.25M shares of common stock and an undisclosed amount of cash (7/99) |
Desmos Inc.* | TheraCyte Inc.* | Research collaboration in which the two companies will explore their combined technologies as a potential treatment for insulin-dependent diabetics |
Desmos will provide pancreatic islets using its expansion and differentiation technologies; TheraCyte will provide the immunoprotective barrier using its encapsulation technology; financial details ND (8/99) |
Endovasc Ltd. (OTC BB:ENDV) |
Hermes Biosciences Inc.* | Development agreement in which the two companies will co-develop a liposomal encapsulation of the vascular growth protein VEGF |
ND (8/99) |
Galileo Genomics* (Canada) |
Myriad Genetics Inc. (MYGN) |
Strategic collaboration in which Myriad will receive access to DNA samples from patients in the French-Canadian population of Quebec | Myriad will acquire a 15% ownership in Galileo through a $0.75M equity investment, and will fund research at Galileo; Myriad has reserved a right of first refusal on DNA samples associated with diseases of potential interest; Myriad will receive exclusive worldwide diagnostic and therapeutic rights for all genes discovered during the collaboration, returning a royalty on any product sales based on these genes to Galileo (9/99) |
Genome Therapeutics Corp. (GENE) | Biogen Inc. (BGEN) |
Sequencing contract under which Genome will use its sequencing techniques, automation, bioinformatics and quality control procedures to generate sequence information in support of research projects underway at Biogen | ND (9/99) |
Genomica Corp.* | Biognosis U.S. Inc.* | Licensing agreement; Biognosis will use Genomica's Discovery Manager software to manage genetic analysis tasks in the course of its psychiatric phenotyping research |
ND (7/99) |
Clingenix Inc.* (formerly GeneAsia Inc.) |
Licensing agreement; Clingenix will use Genomica's Discovery Manager software to enhance its gene discovery research |
ND (9/99) |
|
Orchid Biocomputer Inc.* |
Licensing agreement; Orchid will use Genomica's Discovery Manager software with its pharmacogenetics and Genotyping Center of Excellence to increase the speed and efficiency of its genetic bit analysis technology developed to analyze single nucleotide polymorphisms |
ND (9/99) | |
Genovo Inc.* (GENZ) |
Genzyme General |
Collaboration agreement to develop gene therapy products for lysosomal storage disorders using Genovo's proprietary viral vectors |
Genovo will conduct research and development activities to develop one gene therapy product through the successful completion of a Phase I trial; Genzyme subsequently will have the option to pursue further development of that product, and to develop additional gene therapy products, in collaboration with Genovo or on its own; Genzyme has been granted an exclusive, worldwide license to all of Genovo's vector patents and technology for use in developing and commercializing gene therapy products for lysosomal storage disorders; Genovo will receive product development milestone payments and royalties on product sales; Genzyme will also make an equity investment in Genovo, and has the option to make additional equity investments (8/99) |
Genzyme Molecular Oncology (GZMO) |
Hybridon Inc. (OTC BB:HYBN) | License agreement; Hybridon receives a non-exclusive license to patent rights relating to antisense compounds that interfere with the cancer-related protein MDM2, methods for treating cancers with these compounds, and methods for identifying such compounds; these patent rights are exclusively licensed to Genzyme by Johns Hopkins University |
In exchange for the patent rights, Genzyme receives an up-front payment; if Hybridon successfully develops therapeutic products through the use of these rights, Genzyme could receive milestone payments and royalties on product sales (9/99) |
Gilead Sciences Inc. (GILD) |
Medarex Inc. (MEDX) | Development agreement; Medarex obtained an exclusive sublicense from Gilead to the CTLA-4 Blockade intellectual property rights owned by the University of California, Berkeley, to pursue methods of blocking CTLA-4 | Under the terms of the agreement, Medarex also has an option to pursue certain other non-antibody-based methods of block ing CTLA-4; further details ND (8/99) |
GPC AG* (Germany) |
Novalon Pharmaceutical Corp.* | Drug discovery collaboration for the development of a new generation of broad-spectrum antibiotics, based on a novel class of genomics-derived | GPC will provide Novalon with novel antibacterial targets that have been identified and validated using GPC's integrated second-generation genomics technologies; Novalon will develop high-throughput screening assays, based on its BioKey assay technology, to screen small-molecule compound libraries and identify lead compounds with antibacterial activity; on successful completion of the collaboration, the companies may enter into a broader alliance for additional targets from GPC's internal antibacterial research program; financial details ND (9/99) |
Iconix Pharmaceuticals Inc.* |
Metabolex Inc.* |
R&D collaboration focused on target validation and small-molecule drug discovery for genes believed to influence diabetes | Iconix will apply its proprietary assay platform and chemical diversity library to identify small-molecule modulators of potential diabetes-related genes identified by Metabolex; further details ND (8/9) |
Igen International Inc. (IGEN) | Biogen Inc.* | Product agreement in which Biogen will use Igen's M-Series high-through-put screening system for its drug discovery and development programs | ND (7/99) |
Ilex Oncology Inc. (ILXO) | Impath Inc. (IMPH) | Collaboration agreement under which Impath will provide anatomic and molecular pathology services for Ilex, with the intent of creating state-of-the-art services to advance international drug development | Impath made a $5M equity investment in Ilex via a private placement of preferred stock; further details ND (9/99) |
ImmGenics Pharmaceuticals Inc.* (Canada) |
Genzyme Corp.* |
Co-development agreement in which ImmGenics will work with Genzyme, using its SLAM technology to develop a high-affinity biotherapeutic monoclonal antibody to an undisclosed antigen target |
ND (9/99) |
Incyte Pharmaceuticals Inc. | Genentech Inc. (NYSE:DNA) |
Expansion and extension of 1/97 genomic database partnership; the expanded agreement provides Genentech access to Incyte's LifeSeq Gold assembled database, and includes a partnering program in bioinformatics |
Incyte could receive future milestone payments and royalties on sales of products developed with its technology and database information; financial details ND (7/99) |
Millennium Pharmaceuticals Inc. (MLNM) |
Genomic database partnership whereby Millennum will gain access to Incyte's LifeSeq Gold assembled database, as well as Incyte's LifeTools data management software |
Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information; financial details ND (10/99) |
|
Lexicon Genetics Inc.* |
Avatar BioSci Inc.* | Research agreement; Lexicon will sublicense to Avatar a segment of its Gene Trapping Vector Technology for the discovery of new drug targets in the areas of infectious diseases and cancer |
Lexicon will receive an equity position of convertible preferred stock in Avatar, as well as two five-year warrants to purchase additional equity; Lexicon is also eligible for downstream rights from products developed and commercialized using its Gene Trapping technology (9/99) |
Millennium Pharmaceuticals Inc. (MLNM) | Collaboration agreement; Lexicon will use its portfolio of homologous recombination technologies to create genetically engineered mice for use by Millennium in the validation of potential drug targets identified and selected by Millennium |
Lexicon will generate a significant number of mice for Millennium over a three-year period; Millennium will select specified minimum numbers of mice during each year of the collaboration; financial terms ND (7/99) | |
Lexicon Genetics Inc.* | Millennum Pharmaceuticals Inc. (MLNM) |
Research agreement; Millennium and its affiliates will have access to Lexicon's Human Gene Trap and OmniBank databases for the discovery and development of drugs and diagnostic products |
Lexicon will receive annual access fees, and may receive license fees, milestone payments and royalties on sales of drugs and diagnostic products developed with its technology and database information; (10/99) |
LigoCyte Pharmaceuticals Inc.* | Corixa Corp. (CRXA) | License and research agreement; Corixa will use Candida technology for the development of therapeutic and vaccine products that target infections arising from Candida albicans |
LigoCyte will receive equity funding, license fees, research funding and milestone payments based on successful clinical and commercial progress, as well as a royalty on future product sales; further financial details ND (10/99) |
Medarex Inc. (MEDX) |
Amgen Inc. (AMGN) |
Antibody development collaboration in which Medarex will use its HuMAb-Mouse technology to generate fully human monoclonal antibodies to multiple targets for Amgen |
Medarex will receive research and development payments from Amgen, and could receive additional fees and milestone payments, plus royalties on future product sales; Amgen will be responsible for product development, manufacturing and marketing of any products developed through the collaboration (9/99) |
Eos Biotechnology Inc.* |
Antibody development collaboration in which Eos will have access to Medarex's HuMAb-Mouse technology for the generation of fully human antibodies to Eos' genomics-derived immunotherapeutic targets | Medarex could receive research payments, license fees and milestone payments, as well as royalties on therapeutic product sales (8/99) | |
Millennium Pharmaceuticals Inc. (MLNM) |
Cetek Corp.* | Research agreement allowing Millennium to evaluate Cetek's proprietary screening technology in screening genomic targets |
Cetek will develop assays and screens against compound libraries from Millennium; further details ND (9/99) |
Neogenesis Inc.* | Creative BioMolecules Inc. | Research agreement in which Creative BioMolecules will have access to Neo-genesis's library of small molecules and screening approaches to advance and accelerate its drug discovery process |
ND (7/99) |
Neurochem Inc.* (Canada) |
Resolution Pharmaceuticals Inc.* | R&D collaboration to develop radio imaging diagnostic agents targeted at amyloid deposits associated with Alzheimer's disease | The companies will jointly identify and develop products resulting from the combination of Neurochem's amyloid targeting molecules and Resolution's radioimaging platform technology; subsequent development of lead molecules will be carried out by both companies; financial details ND (7/99) |
Phylos Inc.* (CBST) |
Cubist Pharmaceuticals Inc. | Collaboration agreement using Phylos' Profusion technology for the identification of peptide-like agents that bind with high affinity to protein targets |
The agents identified in the collaboration will be incorporated into Cubist's VITA (Validation In Vivo for Targets and Assays for Anti-infectives) technology and for the development of high-through-put screening assays; Phylos will receive research funding and, if applicable, milestone payments during the term of the agreement (10/99) |
Prometic Biosciences Inc.* (a subsidiary of Prometic Life Sciences Inc.; Canada) | Powderject Pharmaceuticals plc (UK; LSE:PJP) |
Collaboration agreement combining Prometic's particle technology with Powderject's needle-free delivery system |
Powderject will receive a global license to use Prometic's technology in the development and commercialization of pharmaceutical compounds for administration via Powderject's needle-free delivery system; Prometic will receive collaboration fees and manufacturing rights (9/99) |
Sangamo Biosciences Inc.* | Genset SA* (France) |
Research agreement; Sangamo will provide specific Universal GeneTools to Genset for use in its target validation programs |
ND (9/99) |
Immunex Corp.* | Research agreement; Sangamo will provide specific Universal GeneTools to Immunex for use in its internal research and validation programs |
ND (9/99) | |
Sequenom Inc.* |
Genzyme Genetics (a unit of Genzyme Corp.) |
License agreement for the development of mutation detection assays using Sequenom's MassArray and SpectroChips technologies | ND (9/99) |
Sequitur Inc.* |
Genome Therapeutics Corp. (GENE) | Expansion of research collaboration; Genome receives non-exclusive access to Sequitur's antisense functional genomics technology and to high-specificity antisense compounds, cellular delivery compounds and proprietary computer target site selection technology |
ND (9/99) |
Structural Bioinformatics Inc.* |
BioChem Pharma Inc. (Canada; BCHE) | Research collaboration for generating and optimizing lead compounds for thre treatment of a ND viral infectious disease |
Structural Bioinformatics will work with BioChem scientists using its proprietary protein modeling, DynaPharm and CombiLib technologies; BioChem will expand its financial commitments, which encompass research funding and milestone and royalty payments (7/99) |
Xoma Ltd. (XOMA) |
Genentech Inc. (NYSE:DNA) | Expansion of 4/96 hu1124 antibody product development program to include organ transplant rejection | ND (8/99) |
Notes: | |||
@ This chart covers biotech company deals with other biotech companies, and biotech company deals with device, diagnostics and marketing companies announced between 7/1/99 and 10/15/99. It does not include deals in the area of agricultural biotechnology. | |||
* Private companies are indicated with an asterisk. | |||
# Indicates funding partner, where applicable. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq Market. | |||
OTC BB = Over the Counter Bulletin Board; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange | |||
ND = Not disclosed, reported and/or available | |||
